

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version 2.0      Revision Date: 04/09/2021      SDS Number: 4944863-00004      Date of last issue: 10/10/2020  
Date of first issue: 09/30/2019

### SECTION 1. IDENTIFICATION

Product name : Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation  
Other means of identification : No data available

#### Manufacturer or supplier's details

Company name of supplier : Organon & Co.  
Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302  
Telephone : 551-430-6000  
Emergency telephone : 215-631-6999  
E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the Hazardous Products Regulations

Combustible dust : Category 1  
Eye irritation : Category 2A  
Reproductive toxicity : Category 1A  
Specific target organ toxicity - repeated exposure : Category 1 (Kidney, Parathyroid gland)

#### GHS label elements

Hazard pictograms :

Signal Word : Danger

Hazard Statements : May form combustible dust concentrations in air.  
H319 Causes serious eye irritation.  
H360D May damage the unborn child.  
H372 Causes damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0      Revision Date: 04/09/2021      SDS Number: 4944863-00004      Date of last issue: 10/10/2020  
Date of first issue: 09/30/2019

P260 Do not breathe dust.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P280 Wear protective gloves, protective clothing, eye protection and face protection.

### Response:

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P308 + P313 IF exposed or concerned: Get medical attention.

P337 + P313 If eye irritation persists: Get medical attention.

### Storage:

P405 Store locked up.

### Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

### Other hazards

|| Contact with dust can cause mechanical irritation or drying of the skin.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Cellulose	No data available	9004-34-6	$\geq 30 - < 60$ *
Starch	Sago starch	9005-25-8	$\geq 30 - < 60$ *
Olmesartan	No data available	144689-63-4	$\geq 10 - < 30$ *
Hydrochlorothiazide	No data available	58-93-5	$\geq 5 - < 10$ *
Amlodipine Besylate	No data available	652969-01-2	$\geq 1 - < 5$ *

\* Actual concentration or concentration range is withheld as a trade secret

## SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0      Revision Date: 04/09/2021      SDS Number: 4944863-00004      Date of last issue: 10/10/2020  
Date of first issue: 09/30/2019

- Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Causes serious eye irritation.  
May damage the unborn child.  
Causes damage to organs through prolonged or repeated exposure.  
Contact with dust can cause mechanical irritation or drying of the skin.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : High volume water jet
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Do not use a solid water stream as it may scatter and spread fire.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Chlorine compounds  
Sulfur oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protection : Use personal protective equipment.

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
2.0	04/09/2021	4944863-00004	Date of first issue: 09/30/2019

- tive equipment and emergency procedures : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Do not get in eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Organic peroxides

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version 2.0      Revision Date: 04/09/2021      SDS Number: 4944863-00004      Date of last issue: 10/10/2020  
 Date of first issue: 09/30/2019

Explosives  
Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Total dust)	10 mg/m <sup>3</sup>	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m <sup>3</sup>	CA BC OEL
		TWAEV (total dust)	10 mg/m <sup>3</sup>	CA QC OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Starch	9005-25-8	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWAEV (total dust)	10 mg/m <sup>3</sup>	CA QC OEL
		TWA (Total dust)	10 mg/m <sup>3</sup>	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m <sup>3</sup>	CA BC OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Olmesartan	144689-63-4	TWA	30 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	300 µg/100 cm <sup>2</sup>	Internal
Hydrochlorothiazide	58-93-5	TWA	100 µg/m <sup>3</sup> (OEB 2)	Internal
Amlodipine Besylate	652969-01-2	TWA	20 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal

**Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

#### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.  
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
2.0	04/09/2021	4944863-00004	Date of first issue: 09/30/2019

---

Skin and body protection : Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hygiene measures : Work uniform or laboratory coat.

: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : tablet

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : Not applicable

Flammability (solid, gas) : No data available

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version 2.0      Revision Date: 04/09/2021      SDS Number: 4944863-00004      Date of last issue: 10/10/2020  
Date of first issue: 09/30/2019

---

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Dust can form an explosive mixture in air.  
Can react with strong oxidizing agents.

Conditions to avoid : Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg  
Method: Calculation method

#### Components:

##### Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

---

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0      Revision Date: 04/09/2021      SDS Number: 4944863-00004      Date of last issue: 10/10/2020  
Date of first issue: 09/30/2019

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

### Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

### Olmesartan:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
LD50 (Mouse): > 2,000 mg/kg  
LD50 (Dog): > 1,500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

### Hydrochlorothiazide:

Acute oral toxicity : LD50 (Rat): > 2,750 mg/kg  
LD50 (Mouse): > 2,830 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 990 mg/kg  
Application Route: Intravenous  
LD50 (Mouse): 590 mg/kg  
Application Route: Intravenous

### Amlodipine Besylate:

Acute oral toxicity : LD50 (Rat): 393 mg/kg

### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Olmesartan:

Remarks : No data available

#### Hydrochlorothiazide:

Species : Rabbit  
Result : No skin irritation



**Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation**

Version 2.0      Revision Date: 04/09/2021      SDS Number: 4944863-00004      Date of last issue: 10/10/2020  
Date of first issue: 09/30/2019

---

**Serious eye damage/eye irritation**

Causes serious eye irritation.

**Components:****Starch:**

Species : Rabbit  
Result : No eye irritation

**Olmesartan:**

Species : Rabbit  
Result : Moderate eye irritation  
Method : Draize Test

**Hydrochlorothiazide:**

Species : Rabbit  
Result : Mild eye irritation

**Amlodipine Besylate:**

Species : Rabbit  
Result : Severe irritation

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Components:****Starch:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative

**Olmesartan:**

Routes of exposure : Skin contact  
Remarks : No data available

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

**Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
2.0	04/09/2021	4944863-00004	Date of first issue: 09/30/2019

Genotoxicity in vivo	:	Test Type: In vitro mammalian cell gene mutation test
		Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
		Species: Mouse
		Application Route: Ingestion
		Result: negative

**Starch:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Result: negative

**Olmesartan:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Result: negative
		Test Type: Mutagenicity (in vitro mammalian cytogenetic test)
		Result: negative
Genotoxicity in vitro	:	Test Type: Chromosome aberration test in vitro
		Test system: Chinese hamster lung cells
		Result: positive
Genotoxicity in vivo	:	Test Type: Mouse Lymphoma
		Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test
		Species: Mouse
		Cell type: Bone marrow
		Application Route: Oral
		Result: negative
Germ cell mutagenicity - Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

**Hydrochlorothiazide:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Result: negative
Genotoxicity in vitro	:	Test Type: Chromosomal aberration
		Test system: Chinese hamster ovary cells
		Result: negative
Genotoxicity in vitro	:	Test Type: sister chromatid exchange assay
		Test system: Chinese hamster ovary cells
		Result: positive
Genotoxicity in vitro	:	Test Type: in vitro test
		Test system: mouse lymphoma cells
		Result: positive

**Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
2.0	04/09/2021	4944863-00004	Date of first issue: 09/30/2019

Genotoxicity in vivo	:	Test Type: Chromosomal aberration Species: Chinese hamster Cell type: Bone marrow Result: negative
		Test Type: in vivo assay Species: Mouse Cell type: Bone marrow Result: negative
Germ cell mutagenicity - Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

**Amlodipine Besylate:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosome aberration test in vitro Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:**
**Cellulose:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	72 weeks
Result	:	negative

**Olmesartan:**

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
Result	:	negative

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	6 Months
Result	:	negative

**Hydrochlorothiazide:**

Species	:	Mouse, female
Application Route	:	Oral
Exposure time	:	2 Years
Result	:	negative

Species	:	Mouse, male
Application Route	:	Oral

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0      Revision Date: 04/09/2021      SDS Number: 4944863-00004      Date of last issue: 10/10/2020  
Date of first issue: 09/30/2019

Exposure time : 2 Years  
Result : equivocal

Species : Rat, male and female  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

### Amlodipine Besylate:

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

### Reproductive toxicity

May damage the unborn child.

### Components:

#### Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

#### Olmesartan:

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 1,000 mg/kg body weight  
Result: No effects on fertility.

Effects on fetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Dose: 1000 milligram per kilogram  
Result: No teratogenic effects.

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Dose: 1 milligram per kilogram

**Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
2.0	04/09/2021	4944863-00004	Date of first issue: 09/30/2019

Result: No teratogenic effects.

Test Type: Development  
 Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: LOAEL:  $\geq$  1.6 mg/kg body weight  
 Symptoms: Malformations were observed., Reduced body weight  
 Result: Effects on postnatal development.

Reproductive toxicity - Assessment : Positive evidence of adverse effects on development from human epidemiological studies.

**Hydrochlorothiazide:**

Effects on fertility : Test Type: Fertility  
 Species: Rat, male and female  
 Application Route: oral (feed)  
 Fertility: NOAEL: 4 mg/kg body weight  
 Result: Effects on fertility.

Test Type: Fertility  
 Species: Mouse, male and female  
 Application Route: oral (feed)  
 Fertility: NOAEL: 100 mg/kg body weight  
 Result: Effects on fertility.

Effects on fetal development : Test Type: Development  
 Species: Mouse  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: 3,000 mg/kg body weight  
 Result: No teratogenic effects.

Test Type: Development  
 Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: 1,000 mg/kg body weight  
 Result: No teratogenic effects.

**Amlodipine Besylate:**

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Ingestion  
 Fertility: NOAEL: 10 mg/kg body weight  
 Result: No effects on fertility.

Test Type: Fertility/early embryonic development  
 Species: Rabbit  
 Application Route: Ingestion  
 Fertility: NOAEL: 25 mg/kg body weight  
 Result: No effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

**Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
2.0	04/09/2021	4944863-00004	Date of first issue: 09/30/2019

Species: Rat  
 Application Route: Ingestion  
 Developmental Toxicity: LOAEL: 10 mg/kg body weight  
 Result: Effects on fetal development.

Test Type: Embryo-fetal development  
 Species: Rabbit  
 Application Route: Ingestion  
 Developmental Toxicity: NOAEL: 10 mg/kg body weight  
 Result: No effects on fetal development.

Test Type: Embryo-fetal development  
 Species: Mouse  
 Application Route: Ingestion  
 Developmental Toxicity: LOAEL: 1.6 mg/kg body weight  
 Result: Effects on fetal development.  
 Remarks: Maternal toxicity observed.

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

Causes damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.

**Components:****Hydrochlorothiazide:**

Target Organs	:	Kidney, Parathyroid gland
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Cellulose:**

Species	:	Rat
NOAEL	:	>= 9,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

**Starch:**

Species	:	Rat
NOAEL	:	>= 2,000 mg/kg
Application Route	:	Skin contact
Exposure time	:	28 Days
Method	:	OECD Test Guideline 410

**Olmesartan:**

Species	:	Rat
NOAEL	:	2,000 mg/kg
Application Route	:	Oral

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version 2.0      Revision Date: 04/09/2021      SDS Number: 4944863-00004      Date of last issue: 10/10/2020  
Date of first issue: 09/30/2019

Exposure time : 24 Months  
Remarks : No significant adverse effects were reported

### Hydrochlorothiazide:

Species : Rat, male and female  
LOAEL : 10 mg/kg  
Application Route : Oral  
Exposure time : 2 y  
Target Organs : Kidney, Parathyroid gland

Species : Mouse, male and female  
NOAEL : 300 - 550 mg/kg  
Application Route : Oral  
Exposure time : 2 y  
Remarks : No significant adverse effects were reported

Species : Dog  
Application Route : Oral  
Exposure time : 9 Months  
Target Organs : Parathyroid gland

### Amlodipine Besylate:

Species : Rat  
NOAEL : 15 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

### Aspiration toxicity

Not classified based on available information.

### Components:

#### Hydrochlorothiazide:

No aspiration toxicity classification

### Experience with human exposure

### Components:

#### Olmesartan:

Eye contact : Symptoms: Eye irritation  
Ingestion : Symptoms: hypotension  
Remarks: May cause harm to the unborn child.  
Based on Human Evidence

#### Hydrochlorothiazide:

Eye contact : Symptoms: Eye irritation  
Ingestion : Symptoms: Dizziness, Headache, Fatigue, Nausea, Abdominal pain, hypotension, dry mouth, electrolyte imbalance, eye pain

# Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
2.0	04/09/2021	4944863-00004	Date of first issue: 09/30/2019

**Amlodipine Besylate:**

Eye contact	: Symptoms: Severe irritation
Ingestion	: Symptoms: Nausea, Abdominal pain, Fatigue, Headache, Edema, Palpitation

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish	: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	--------------------------------------------------------------------------------------------------------------------------------

**Hydrochlorothiazide:**

Toxicity to fish	: LC50 (Pimephales promelas (fathead minnow)): > 500 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 500 mg/l Exposure time: 48 h

**Amlodipine Besylate:**

Toxicity to fish	: LC50 (Pimephales promelas (fathead minnow)): 2.7 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 3.2 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	: IC50 (Pseudokirchneriella subcapitata (green algae)): 5.6 mg/l Exposure time: 72 h Method: OECD Test Guideline 201

**Persistence and degradability****Components:****Cellulose:**

Biodegradability	: Result: Readily biodegradable.
------------------	----------------------------------

**Hydrochlorothiazide:**

Stability in water	: Hydrolysis: 46.2 %(96 h)
--------------------	----------------------------

**Bioaccumulative potential****Components:****Amlodipine Besylate:**

Partition coefficient: n-	: log Pow: 3
---------------------------	--------------



# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version 2.0      Revision Date: 04/09/2021      SDS Number: 4944863-00004      Date of last issue: 10/10/2020  
Date of first issue: 09/30/2019

---

|| Octanol/water

### Mobility in soil

No data available

### Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Domestic regulation

#### TDG

Not regulated as a dangerous good

---

## SECTION 15. REGULATORY INFORMATION

### The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

---

## SECTION 16. OTHER INFORMATION

### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)

---

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
2.0	04/09/2021	4944863-00004	Date of first issue: 09/30/2019

CA BC OEL	:	Canada. British Columbia OEL
CA QC OEL	:	Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA	:	8-hour, time-weighted average
CA AB OEL / TWA	:	8-hour Occupational exposure limit
CA BC OEL / TWA	:	8-hour time weighted average
CA QC OEL / TWAEV	:	Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <a href="http://echa.europa.eu/">http://echa.europa.eu/</a>
--------------------------------------------------------------------	---	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Revision Date	:	04/09/2021
Date format	:	mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
2.0	04/09/2021	4944863-00004	Date of first issue: 09/30/2019

---

shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8